The term **psychobiotic** is used to mean a live organism that, when ingested in adequate amounts, produces a health benefit in patients suffering from psychiatric illness. In this context, a psychobiotic must be capable of **producing and delivering neuroactive substances** such as gamma-aminobutyric acid (GABA) and serotonin, which act on the brain–gut axis. These bacteria can therefore exert anxiolytic and antidepressant effects characterized by changes in emotional, cognitive, systemic, and neural indices. However, the authors note that while animal work is compelling, **translation to humans is still in its infancy**, with relatively few and often small human trials available.

The review states that "clinical, epidemiological, and immunological evidence suggest that enteric microbiota extensively and profoundly influences the gut-brain relationship (ie, the microbiota-gut-brain axis)." It notes that gut microbes can affect the central nervous system through immune, neural (vagus nerve), and endocrine pathways, and that preclinical work shows microbiota can influence anxiety-like and depressive-like behaviors. However, the authors emphasize that much of the human literature is associative and that causal mechanisms and effect sizes in humans remain to be clearly defined.

Gut bacteria play an important role in the digestion of food, immune activation, and regulation of entero-endocrine signaling pathways, but also communicate with the central nervous system (CNS) through the production of specific metabolic compounds, e.g., bile acids, short-chain fatty acids (SCFAs), glutamate (Glu), γ-aminobutyric acid (GABA), dopamine (DA), norepinephrine (NE), serotonin (5-HT) and histamine. Although 5-HT is synthesized by neurons of the ENS, more than 90% of 5-HT is produced in the gut by enterochromaffin cells (ECCs). Some authors claim that as much as 80% of 5-HT in the gastrointestinal tract is produced by gut bacteria such as Escherichia coli, Hafnia, Bacteroides, Streptococcus, Bifidobacterium, Lactococcus, Lactobacillus, Morganella, Klebsiella, Propionibacterium, Eubacterium, Roseburia and Prevotella. Gut bacteria use primarily GABA, DA, NE, 5-HT and histamine to communicate with the CNS, but also intermediate compounds, notably SCFAs, tryptophan and secondary bile acids.

The gut microbiota has a clear impact on neurotransmitters including serotonin, dopamine, GABA, and glutamate. Findings from studies on animal models concluded that host tryptophan availability could be limited by manipulation of the microbiome and subsequently tryptophan metabolic pathways. The accommodating bacteria effect on brain functions via the gut serotonin system was recognized in a study that found that spore-forming bacteria could directly stimulate serotonin biosynthesis via a complex metabolite/cell component-sustained mechanism in the enterochromaffin cells inside the mice and human GI tract. In conclusion, emerging research emphasizes the significant role of the gut microbiota in mental disorders, particularly through the gut–brain axis, but it highlights that mechanisms often involve modulation of host pathways (such as tryptophan and serotonin metabolism) rather than simple direct transfer of bacterial neurotransmitters to the brain.

This randomized, double-blind, placebo-controlled trial (NCT04823533) in 135 healthy adults tested 4 weeks of **probiotic supplementation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)** on well-being, quality of life, emotional regulation, anxiety, mindfulness and interoceptive awareness. The authors report: "**we found no significant effect of probiotics on a set of psychological measures of well-being, anxiety, emotional regulation, interoception, and mindfulness in a general population sample** qualified as otherwise healthy." They add that beneficial effects on anxiety and emotion regulation emerged only in participants with **high Healthy Behaviors scores**, concluding that "when considering the whole population, we observed no significant difference between groups" on these psychological outcomes.

This 2025 review describes the gut microbiome as "a pivotal modulator of brain function and mental health" via bidirectional communication along the gut–brain axis. It explains that microbial communities influence "neurodevelopment, neurotransmission, and behavior via pathways involving the vagus nerve, immune signaling, and microbiota-derived metabolites such as short-chain fatty acids and neurotransmitter precursors." The article also notes that despite mounting evidence, current studies often have correlational designs, small sample sizes, and methodological limitations, and calls for rigorous, large-scale clinical trials to clarify causality and clinical relevance.

This Nature Microbiology paper (Valles-Colomer et al.) analyzes the gut microbiome of over 1,000 individuals and reports that certain bacterial taxa show associations with quality of life and depression. The authors provide a catalog of gut bacteria with the genetic potential to synthesize or metabolize neuroactive compounds, including neurotransmitters and precursors. They conclude that although there is "neuroactive potential" in the gut microbiome correlating with mental health measures, the cross-sectional design does not allow inference of direct causality or the magnitude of behavioral influence in humans.

Appreciable evidence shows that gut microbiota produce diverse neuroactive metabolites, particularly neurotransmitters (and their precursors), stimulating the neuronal network of the host and thereby modulating brain functionality and behavior. Some gut commensal microbes produce GABA, such as Bacteroides, Bifidobacterium, and Lactobacillus genera. Recently, Sultan et al. (2022) reported a high GABA production (3–6 mM) for Bacteroides finegoldii, B. caccae, and B. faecis, three human gut isolates having a distinctive signature operon compared to low GABA-producing isolates. Gut microbiota also indirectly take part in the production of serotonin: for instance, enterochromaffin cells produce serotonin once they receive signals through gut microbiome-produced metabolites that upregulate expression of the tph1 gene. It is noteworthy that gut-produced serotonin may indirectly impact central serotonergic pathways, even if serotonin itself does not cross the blood–brain barrier, by modulating tryptophan and tryptamine availability.

The gut microbiota is a key regulator of gut–brain axis signaling, capable of producing and modulating a wide range of neuroactive compounds including GABA, serotonin, catecholamines and short-chain fatty acids. Despite substantial production of these molecules in the intestinal lumen, their direct entry into the brain is limited by the blood–brain barrier. Consequently, microbiota effects on brain function are thought to occur mainly through indirect pathways such as immune activation, modulation of enteroendocrine cells, and vagal afferent signaling, rather than by bulk transfer of microbial neurotransmitters to the central nervous system.

The review states that gut bacteria "may produce neurotransmitters such as serotonin and GABA, which can impact mood and behavior." It explains that microbial metabolites and neurotransmitters signal via the vagus nerve, immune pathways, and endocrine mechanisms, contributing to neurodevelopment and behavior. However, it emphasizes that most human data are associative and that mechanistic, causal links in humans remain to be fully elucidated.

This review explains that gut microbes can produce and modulate a wide range of neuroactive molecules, including serotonin, GABA, dopamine, and short-chain fatty acids, which can act on the enteric nervous system and communicate with the brain. It summarizes animal studies showing that germ-free or antibiotic-treated rodents exhibit altered stress responses, anxiety-like behavior, and social behavior that can be partially normalized by specific microbial colonization. The authors emphasize that while these findings demonstrate that the microbiome can influence behavior, data on "direct" effects on complex, stable human personality traits are limited and that human studies are mostly correlational.

This 2026 review summarizes human clinical trials of psychobiotics. It states that **probiotics targeting the gut–brain axis have shown strain- and context-specific effects on anxiety, stress, depression, and cognitive function**. Some trials report improvements in mood, anxiety, sleep quality, or cognitive performance, while **other studies show limited or no effects, particularly in healthy individuals with low baseline stress**. Mechanistically, the review notes that psychobiotics may influence "**neuroactive metabolites, short-chain fatty acids, γ-aminobutyric acid, serotonin, and anti-inflammatory pathways**, thereby modulating cognitive and emotional processes." The authors emphasize that **evidence remains heterogeneous** and that more rigorous, longer-term, and mechanistically grounded trials are needed before firm conclusions about broad personality changes can be drawn.

The article highlights that "gut microbiota disruptions cause neurodegenerative and neuropsychiatric diseases, causing inflammation, oxidative stress, and altered neurotransmission" through the microbiota–gut–brain axis. It details that gut microbes synthesize or modulate neurotransmitters and their precursors, which can influence stress responses, mood and cognitive functions. The review also emphasizes that despite strong evidence from animal models, human data are still emerging and that direct links to stable personality traits are not yet established.

The gut microbiota can modulate host behavior via multiple mechanisms including the production of neuroactive metabolites, modulation of the immune system, and regulation of the hypothalamic–pituitary–adrenal (HPA) axis. Microbial-derived neurotransmitters such as GABA, dopamine, norepinephrine and serotonin are produced in the gut lumen but do not cross the blood–brain barrier in appreciable amounts. Instead, the gut microbiota influence brain function and behavior indirectly, for example by altering tryptophan metabolism, producing short-chain fatty acids, and affecting vagal nerve signaling. Evidence linking specific microbiome changes to psychiatric disorders remains largely correlational, and causal pathways to stable personality traits in humans are not yet clearly established.

Needham, Kaddurah-Daouk and Mazmanian review evidence that gut microbes produce a variety of molecules, including neurotransmitters (e.g., GABA, serotonin, dopamine) and their precursors, that can modulate host neural circuits and behavior. They state that microbial molecules can affect brain regions involved in stress, reward, and social behavior and may contribute to psychiatric and neurodegenerative conditions. However, they emphasize that most mechanistic data are from rodent models and that causality and effect sizes in humans remain incompletely characterized.

Gut microbes can produce a large variety of neuroactive molecules, including serotonin, dopamine, GABA and acetylcholine, or influence their production by host cells. However, most of these microbiota-derived neurotransmitters cannot cross the blood–brain barrier, so they act locally in the gut or on the enteric nervous system, or signal to the brain indirectly via the vagus nerve and immune and endocrine pathways. The review notes that alterations in gut microbiota composition have been associated with depression, anxiety and autism spectrum disorders, but the current evidence in humans is insufficient to draw firm conclusions about direct microbiota control of complex personality traits.

Mayer et al. describe how gut microbes can influence brain function and behavior via the vagus nerve, immune pathways, tryptophan metabolism, and microbial production of neuroactive compounds. They note that germ-free and antibiotic-treated rodents exhibit altered stress reactivity and social behavior that can be normalized by microbiota manipulation, suggesting causal effects of microbes on behavior in animals. The authors stress that, in humans, current evidence primarily links microbiota composition with psychiatric symptoms rather than stable personality traits, and that direct causal pathways are still under investigation.

Reporting on a Nature Microbiology study, the article states that researchers "have found most human gut bacteria do produce neurotransmitters, which are chemicals like dopamine and serotonin that enable communication among neurons" in both the brain and enteric nervous system. It adds that these neurotransmitters "are known to influence intestinal functions, but also our mood and behavior." The study found two genera, Coprococcus and Dialister, were consistently depleted in people diagnosed with depression, but stresses that "it does not mean that these bacteria cause depression" and that more research is needed to assess causality.

The APA article summarizes research showing that "the gut microbiome can influence neural development, brain chemistry and a wide range of behavioral phenomena, including emotional behavior, pain perception and how the stress system responds." It explains that gut bacteria can produce and modulate neurotransmitters such as gamma-aminobutyric acid (GABA), serotonin, and dopamine, and that animal studies suggest changes in microbiota can alter anxiety-like behavior. At the same time, it notes that most evidence for behavioral effects comes from animal models, and that scientists are still clarifying how strongly and in what ways these gut-derived signals translate to human psychological traits.

Oxford researcher Katerina Johnson reports that in a large human study "**both gut microbiome composition and diversity were related to differences in personality, including sociability and neuroticism**." The news release explains that numerous bacterial types previously associated with autism were "**also related to differences in sociability in the general population**." However, the study is cross-sectional: Johnson notes that "**since this is a cross-sectional study, future research may benefit from directly investigating the potential effect these bacteria may have on behaviour**" and that causal influence of the microbiome on personality has not yet been demonstrated. The article also highlights associations between microbiome diversity and social network size, stress, diet, and other lifestyle factors.

The APA Monitor article states that "**evidence is mounting that microorganisms in the gut influence mental health**" and discusses emerging work on psychobiotics. It notes that gut bacteria can **produce neurotransmitters such as GABA, serotonin and dopamine**, and that they interact with the brain via neural, immune and endocrine pathways. At the same time, psychologists quoted in the piece caution that while animal studies often show striking behavioural changes when the microbiome is manipulated, **human evidence is more modest and inconsistent**, with many small or short-duration trials. The article emphasizes that **designing a ‘healthy microbiome’ to reliably alter mood or personality is likely to be complex**, and that strong claims about reshaping temperament in humans remain premature.

This outreach piece explains that gut microbes "can produce and stimulate the production of neurotransmitters, like serotonin, which is sometimes called the 'happy chemical'." It notes that these gut-derived chemicals and other microbial products can influence brain activity through the vagus nerve and blood circulation, potentially affecting mood and behavior. The accompanying explanation underscores that this field is emerging and that scientists are still clarifying how strong these effects are in humans.

This review explains that certain gut bacteria and probiotics can "**synthesize neurochemicals such as GABA, serotonin, and catecholamines**" which can signal to the brain via the vagus nerve, immune mediators, and endocrine pathways. The authors describe human trials where specific probiotic strains led to **reductions in self-reported stress or improvements in mood**, but also highlight trials with null effects. They stress that while **microbial production of neurotransmitters is well documented in vitro and in animal models**, the extent to which these molecules **directly alter human brain levels and complex traits like personality remains unclear**. They call for more mechanistic human studies with neuroimaging and long-term follow-up.

This review discusses evidence linking gut microbiota to personality-related constructs such as anxiety, stress reactivity, and social behavior. It notes that animal studies demonstrate causal effects of microbiota on anxiety-like and social behaviors, often mediated by microbial modulation of neurotransmitters and the HPA axis. For humans, it concludes that data are mostly correlational and that "there is currently insufficient evidence to claim that the microbiome directly shapes core personality traits," though it may modulate affective states related to temperament.

This double-blind, randomized, placebo-controlled trial investigated the effect of a multi-strain probiotic on individuals with **subclinical depressive symptoms**. The authors report that after the intervention, the probiotic group showed a **significant reduction in cognitive reactivity to sad mood**, particularly in rumination and aggressive thoughts, compared with placebo. They interpret these changes as reflecting **state-like vulnerability to depression** rather than shifts in global personality structure. The study did not assess or report changes in standard personality inventories, so it provides **evidence for modulation of mood-related cognitions but not for alterations in core personality traits or temperament**.

This educational overview notes that the gut microbiota can influence the production of neurotransmitters, stating that the gut is involved in synthesizing serotonin, often called the "feel-good" neurotransmitter. It explains that the gut–brain axis involves biochemical signaling between the gastrointestinal tract and the central nervous system and that imbalances in gut bacteria have been linked to mood disorders such as anxiety and depression. The article presents these links as an emerging field and stresses that research is ongoing to understand mechanisms and potential therapeutic implications.

In fact, about 90% of your body’s serotonin is made in the gut, not the brain. This production happens in specialized gut cells known as enterochromaffin cells, and it plays a key role in regulating digestion and gut motility. While gut microbes don’t make serotonin directly, they have a powerful influence on its production and availability—for example, some bacteria can stimulate enterochromaffin cells to make more serotonin, or affect how it is absorbed and recycled. The article notes that gut-made dopamine and serotonin cannot cross the blood–brain barrier, but gut-derived serotonin can still send messages to the brain by stimulating the vagus nerve, influencing how you feel and manage stress. It also explicitly states that science is not yet at a point where we can predict mood or neurotransmitter levels from the microbiome alone.

Multiple microbiology and neurogastroenterology reviews agree that **gut microbes can synthesize large quantities of neurotransmitters (e.g., GABA, serotonin) locally in the intestinal lumen**, but that **most of these molecules do not cross the blood–brain barrier in significant amounts**. Instead, their main relevance is via **local receptor activation on enteric neurons, modulation of vagal afferents, immune signaling, and metabolic changes**. As a result, the mere fact that the gut microbiome produces 'enough' neurotransmitters in the gut does **not** directly imply that those neurotransmitters enter the brain at levels sufficient to reshape stable human personality traits; any influence is likely **indirect, context-dependent, and more evident for transient mood and stress responses** than for enduring temperament.